chronic brain diseases in which ordered protein polymerization is endogenously seeded. A detailed understanding of this process may shed new light on the etiology of these diseases, allow risk factors to be identified, and pave the way for more effective and specific
Ordered Aggregation Requires the Formation of a Seed
Age-related neurodegenerative diseases form a cliniIn contrast to the formation of amorphous precipitate, cally and neuropathologically diverse group that inordered aggregation proceeds via a nucleus (or seed), cludes common sporadic diseases such as Alzheimer's the formation of which is slow due to the high entropic disease (AD) and Parkinson's disease (PD), both of cost of organizing a series of specific intermolecular which also occur in relatively rare early-onset familial interactions. Seeded polymerization will not occur beforms; purely familial diseases such as Huntington's dislow a certain protein concentration known as the critical ease (HD); and "infectious" prion diseases, which are concentration (dark green zone in phase diagrams in transmissible. That each of these diseases is character- Figure 1 ). Above this concentration, aggregation will not ized by abnormal protein deposition in the brain has necessarily occur immediately (the rate of polymerizabeen documented, although a causal role for deposition tion can be extremely sensitive to protein concentrain neurodegeneration has not been proven. However, tion), giving rise to a metastable supersaturated state the significance of the fact that abnormal protein deposi-(light green zone). Addition of preformed ordered aggretion is a shared feature of all of these diseases has gate, or "seed," to a supersaturated solution will result perhaps been underappreciated. It is the purpose of this in immediate aggregation (elimination of the light green Minireview to draw attention to existing evidence that zone; see lower-right phase diagram). Crystallization, suggests that the mechanism of protein aggregation microtubule formation, and sickle-cell hemoglobin fibriland deposition may also be shared and to identify corollization are examples of seeded polymerizations (Eaton laries of this hypothesis that suggest experimental tests and Hofrichter, 1995; Harper and Lansbury, 1997 The in vitro formation of amyloid fibrils, including those PrP Sc ). Conversion involves a change in the three-dimencomprising A␤, occurs via seeded polymerization. A␤ sional rather than the covalent structure of these profibrils comprising A␤40 or the minor variant A␤42, which teins. The conversion of A␤ to amyloid fibrils seems to forms fibrils much more rapidly than A␤40 in vitro, seed be indirectly promoted in early-onset familial AD (FAD) polymerization of A␤40 (Harper and Lansbury, 1997). by mutations in three genes (amyloid precursor protein Significantly, of 11 FAD mutations that have been ana-[APP] and presenilins 1 and 2) that increase its produclyzed in various ways, all increase A␤42 production while tion (Selkoe, 1997). Alternatively, the conversion of PrP only one also increases A␤40 production (Selkoe, 1997). to PrP Sc may be directly promoted in the familial prion Together, these data strongly suggest that A␤42 may diseases by mutations in the gene encoding PrP that produce the pathogenic seed. The in vitro formation of facilitate unfolding and/or aggregation (Prusiner, 1997) .
PrP Sc from the soluble cellular prion protein, using brainRecently, protein aggregation has also been implicated derived PrP Sc as seed, also has properties of a seeded in PD and the group of neurodegenerative diseases aspolymerization, although this model system has not yet sociated with polyglutamine repeats, including HD and been proven to precisely mimic the in vivo process spinocerebellar ataxia type III (SCA3).
( Caughey et al., 1995) . The properties of these stable pathogenic protein aggregates (i.e., A␤ amyloid and PrP Sc ) suggest that their formation involves seeded polymerization of the constitHuntington's Disease and Familial Parkinson's Disease Are Both Caused by Mutations uent proteins (i.e., A␤ and PrP; Harper and Lansbury, 1997) . This hypothesis may also provide a simple explain Genes that Encode Proteins Found in Disease-Associated nation for the transmissability of the prion diseases: the "infectious" particle may be an exogenous seed for PrP Fibrillar Aggregates HD and SCA3, both of which are caused by expansion polymerization. PD, SCA3, and HD may also involve ordered aggregation, and they may, together with AD of preexisting polyglutamine tracts in otherwise unrelated proteins (huntingtin and ataxin-3, respectively), are and the prion diseases, constitute a large group of The process of ordered protein aggregation (e.g., amyloid formation and PrP Sc formation) depends on protein concentration and the time during which supersaturation is maintained. This leads to a time-dependent phase diagram containing three regions. The black circle represents the in vivo conditions. If these conditions fall in the red zone, aggregation will occur and disease will result. If they fall in either of the two green zones, no aggregation will occur. This zone is likely to be experienced in "normal" metabolism (black circle). Several scenarios could trigger aggregation (a move of the black circle into the red zone).
characterized by abnormal nuclear inclusions in the afthis is the basis of cloud seeding. Thus, one might expect that seeds arising from mutant proteins may promote fected brain regions (DiFiglia et al., 1997; Paulson et al., 1997 (Spillantini et al., 1997) . Recently, variant (nuclear inclusions in transgenic mice do not appear to contain endogenous huntingtin). In cell culture a point mutation in the ␣-synuclein gene has been linked to a rare form of early-onset familial PD (Polymeropoulos models of SCA3, wt ataxin-3 is recruited into nuclear inclusions along with the coexpressed mutant protein et al., 1997). Whether the PD mutation increases the tendency of ␣-synuclein to polymerize, analogous to the (Paulson et al., 1997) . In HD, familial PD, and familial prion disease, mutaapparent action of PrP mutations associated with prion diseases, has not been determined.
tions may directly stabilize the seed, accelerating its formation. In contrast, FAD mutations, which do not It is interesting that cortical Lewy bodies often coexist with amyloid plaques in AD brain ("Lewy body variant" involve the A␤ sequence, may indirectly promote seeding by selectively increasing the production of A␤42. of AD) and FAD brain and are also characteristic of diffuse Lewy body disease (DLBD), an age-related de-
The FAD abnormality (analogous to the mutant protein) is increased A␤42, whereas A␤40 is normal (analogous mentia lacking amyloid plaques but often confused with AD in the clinic (Kosaka and Iseki, 1996) . The involveto wt). However, once again the normal protein is involved in the abnormal polymerization: amyloid derived ment of the Lewy body in both AD and PD, albeit in separate regions of the brain, taken together with evifrom the brains of FAD individuals contains A␤40, as do plaques from Down's syndrome AD patients (Selkoe, dence that certain factors may increase susceptibility for both AD and PD, suggests that a common mecha-1997). These may be additional examples of diseaseassociated mutations accelerating seeded polymerizanism may be involved in pathogenesis of all of these diseases.
tion of the normal protein. , 1997) , and a polymorphism in its promoter seems to modify Nucleation and Cause Seeding of Wild-Type Protein Polymerization the AD risk of individuals bearing the apoE4 risk factor (Xia et al., 1996) . A peptide containing a partial ␣-synuSeeding can be accomplished by a heterologous material that is complementary to the polymer of interest.
clein sequence forms amyloid fibrils that seed A␤40 polymerization in vitro (Harper and Lansbury, 1997). For example, ice formation is seeded by silver iodide;
The Seeded Polymerization Scenario Provides factor in sporadic AD, PD, and HD. Alternatively, the endogenously generated seed may be heterologousan Explanation for Known Genetic Effects and Suggests Candidate Susceptibility that is, derived from a molecule other than the aggregating protein in a form that just happens to effectively Factors for Future Study Under normal conditions, amyloidogenic proteins may seed its polymerization. Many candidates for this heterologous seed (e.g., glycolipid, proteoglycan, and serum be exposed to supersaturating conditions but for periods of time insufficient to allow nucleation (black circle in amyloid P component) have been suggested. light green zone in upper-left phase diagram). Abnormal conditions that allow nucleation to occur (red zone in Is the Seed a Viable Therapeutic Target? Because the biochemical mechanisms of neuronal death phase diagrams) in vivo could promote disease. Several possibile scenarios are discussed below and illustrated in these diseases remain a mystery, the available therapies target the consequences of neuronal loss (e.g., in Figure 1 .
Germline Mutations May Promote Nucleation
L-DOPA for PD and acetylcholinesterase inhibitors for AD), rather than its underlying cause. If seeding of polyBy lowering the barrier to nucleus formation, mutations could cause the metastable region to shrink to the point merization is the underlying cause, then the seed, or better yet its precursors, could be a target for therapeuthat "normal" conditions ([protein] and time) are sufficient to allow nucleation (upper-right phase diagram).
tic intervention. By inhibiting nucleation, one could increase the size of the light green metastable region, Point mutations in PrP and ␣-synuclein, the insertion of additional repeat sequences in the N-terminal domain thus providing protection against all of the age-related changes discussed above. This strategy has been effecof PrP, and the expansion of the polyglutamine domains in the proteins associated with triplet expansion distive in the inhibition of sickle-cell hemoglobin fibrillization and the treatment of sickle-cell anemia (Eaton and eases may all promote nucleation.
Compromised Chaperone or Protease
Hofrichter, 1995). Inhibitory activity against A␤ amyloid fibril nucleation has been demonstrated by proteins Function Could Allow Nucleation A decrease in the efficiency of the chaperone or proteosuch as apoE and by small drug-like molecules (Harper and Lansbury, 1997) . The challenge will be to devise a some systems, both of which deal with partially folded or misfolded proteins, could allow nucleation to occur nucleation inhibitor that is specific for the seed-producing protein-protein interaction, is efficiently transported more easily, causing a shrinkage of the light green metastable zone (upper-right phase diagram). Such a deto the brain, and is free of side-effects and toxicity, since chronic administration is likely to be necessary. crease could be linked to aging.
Factors that Prolong Supersaturation
In addition, it will be desirable to treat at-risk individuals before the appearance of symptoms, at which time proWould Allow Nucleation tein deposition is advanced and neurodegeneration is Prolonging the existence of the supersaturated state, effectively irreversible. by decreasing either proteolysis or the efficiency of neuronal protein trafficking, could give nucleation the opSelected Readings portunity to occur (lower-center phase diagram; Harper and Lansbury, 1997). Both trafficking and proteolysis
